Blog
RSS FeedPosted by Michael Wonder on 25 Jul 2021
Patient advocacy organisations and FDA drug approval: lessons from Aduhelm
23 July 2021 - In the wake of last month’s controversial FDA approval of Biogen’s Aduhelm, Alzheimer’s Association CEO Harry ...
Posted by Michael Wonder on 18 Jul 2021
How to integrate evidence from patient preference studies into health technology assessment: a critical review and recommendations
15 July 2021 - Health technology assessment agencies vary in their use of quantitative patient preference data and the extent to ...
Posted by Michael Wonder on 06 Jul 2021
MHRA outlines two year delivery plan with ‘patient first’ focus
6 July 2021 - The UK’s Medicines and Healthcare products Regulatory Agency has revealed its new delivery plan, outlining its ...
Posted by Michael Wonder on 24 Jun 2021
ALS association wants more commitment from the FDA
24 June 2021 - In a response letter to the ALS Association, the U.S. FDA has recognised the unmet therapeutic ...
Posted by Michael Wonder on 24 Jun 2021
Moving patient stories highlight opportunities to strengthen our health care systems for all Australians
24 June 2021 - It was an emotional evening among the nearly 200 in-person and online attendees at Parliament House last ...
Posted by Michael Wonder on 15 Jun 2021
How the patient voice is becoming vital for drug approval
14 June 2021 - Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a ...
Posted by Michael Wonder on 11 May 2021
The pharma industry needs to measure patient experience from the patients’ perspectives
10 May 2021 - The relationship between clinical outcomes and the patient experience — the sum of all of interactions ...
Posted by Michael Wonder on 14 Apr 2021
Patient and public involvement in health technology assessment: a new dawn?
12 April 2021 - Patient and public involvement and engagement have become increasingly embedded in health technology assessment over the last ...
Posted by Michael Wonder on 06 Apr 2021
Development of an international template to support patient submissions in health technology assessments
1 April 2021 - The objective was to develop an international template to support patient submissions in health technology assessments. ...
Posted by Michael Wonder on 28 Mar 2021
MHRA pilot seeks evidence of patient involvement in R&D
25 March 2021 - The UK MHRA has begun a pilot project to encourage patient involvement in drug development, asking ...
Posted by Michael Wonder on 24 Mar 2021
The contribution of French patient and consumer groups to health technology assessments over a 2 year period: an observational retrospective study
22 March 2021 - In 2017, The French National Authority for Health created an open, online, systematic contribution process to enable ...
Posted by Michael Wonder on 22 Feb 2021
EMA plots earlier engagement with patient groups
19 February 2021 - The EMA on Friday announced it will pilot an early engagement program to bring patient and ...
Posted by Michael Wonder on 11 Feb 2021
An institutional ethnographic analysis of public and patient engagement activities at a national health technology assessment agency
9 February 2021 - The practice of public and patient engagement in health technology assessment has spread worldwide, yet gaps in ...
Posted by Michael Wonder on 07 Feb 2021
Patient and public involvement in health technology assessment: update of a systematic review of international experiences
5 February 2021 - This paper summarises the current evidence on patient and public involvement in health technology assessment in order ...
Posted by Michael Wonder on 31 Jan 2021
Evaluation of the impact of patient input in health technology assessments at NICE
29 January 2021 - Accounts of patient experiences are increasingly used in health technology assessment processes. However, we know little about ...